News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
495,396 Results
Type
Article (9748)
Company Profile (142)
Press Release (485505)
Multimedia
Podcasts (14)
Webinars (7)
Section
Business (169405)
Career Advice (580)
Deals (26083)
Drug Delivery (9)
Drug Development (53885)
Employer Resources (20)
FDA (9892)
Job Trends (9051)
News (242487)
Policy (18420)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (623)
Accelerated approval (24)
ADA (21)
Adcomms (2)
Allergies (104)
Alliances (33726)
ALS (113)
Alzheimer's disease (986)
Antibody-drug conjugate (ADC) (268)
Approvals (10508)
Artificial intelligence (344)
ASCO (163)
Autoimmune disease (210)
Automation (32)
Bankruptcy (265)
Best Places to Work (7119)
BIO (37)
BIOSECURE Act (1)
Biosimilars (109)
BioSpace Insights (20)
Biotechnology (89)
Bladder cancer (139)
Brain cancer (36)
Breast cancer (516)
Cancer (3781)
Cardiovascular disease (227)
Career advice (500)
Career pathing (44)
CAR-T (188)
CDC (1)
Celiac Disease (1)
Cell therapy (503)
Cervical cancer (34)
Clinical research (48708)
Collaboration (1273)
Commercialization (4)
Company closure (2)
Compensation (1459)
Complete response letters (35)
COVID-19 (820)
CRISPR (67)
C-suite (758)
Cystic fibrosis (87)
Data (5750)
Decentralized trials (1)
Denatured (6)
Depression (102)
Dermatology (61)
Diabetes (353)
Diagnostics (4262)
Digital health (38)
Diversity (3)
Diversity, equity & inclusion (8)
Drug discovery (161)
Drug pricing (8)
Drug shortages (3)
Duchenne muscular dystrophy (164)
Earnings (74037)
Editorial (4)
Employer branding (2)
Employer resources (25)
Events (89429)
Executive appointments (715)
FDA (12541)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (1005)
Gene editing (131)
Generative AI (11)
Gene therapy (333)
GLP-1 (300)
Government (1070)
Grass and pollen (2)
Guidances (282)
Healthcare (9843)
Hematology (96)
HIV (53)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (101)
Immuno-oncology (59)
Indications (156)
Infectious disease (1015)
Inflammatory bowel disease (133)
Inflation Reduction Act (4)
Influenza (86)
Intellectual property (257)
Interviews (88)
IPO (12534)
IRA (3)
Job creations (2063)
Job search strategy (417)
JPM (1)
Kidney cancer (19)
Labor market (99)
Layoffs (208)
Leadership (20)
Legal (5392)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (521)
Lymphoma (252)
Machine learning (29)
Management (7)
Manufacturing (552)
Marketing (8)
MASH (119)
Medical device (8912)
Medtech (9058)
Mergers & acquisitions (14604)
Metabolic disorders (724)
mRNA (54)
Multiple sclerosis (103)
NASH (4)
Neurodegenerative disease (222)
Neuropsychiatric disorders (41)
Neuroscience (1849)
NextGen: Class of 2026 (3307)
Non-profit (1213)
Now hiring (70)
Obesity (228)
Opinion (32)
Ovarian cancer (161)
Pain (171)
Pancreatic cancer (203)
Parkinson's disease (203)
Partnered (13)
Patents (473)
Patient recruitment (518)
Peanut (38)
People (42276)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15754)
Phase 2 (21752)
Phase 3 (14651)
Pipeline (7284)
Policy (24)
Postmarket research (1607)
Preclinical (6674)
Press Release (34)
Prostate cancer (209)
Psychedelics (7)
Radiopharmaceuticals (198)
Rare diseases (585)
Real estate (3141)
Recruiting (10)
Regulatory (15090)
Reports (31)
Research institute (806)
Resumes & cover letters (79)
Rett syndrome (41)
RNA editing (5)
RSV (49)
Schizophrenia (101)
Series A (159)
Series B (131)
Service/supplier (5)
Sickle cell disease (66)
Special edition (8)
Spinal muscular atrophy (89)
Sponsored (6)
Startups (2124)
Stomach cancer (3)
Supply chain (52)
Tariffs (3)
The Weekly (8)
Vaccines (336)
Venture capital (32)
Weight loss (75)
Women's health (82)
Worklife (16)
Date
Today (73)
Last 7 days (455)
Last 30 days (1670)
Last 365 days (19577)
2026 (12255)
2025 (19735)
2024 (23528)
2023 (27092)
2022 (35197)
2021 (37892)
2020 (34259)
2019 (24588)
2018 (18387)
2017 (19200)
2016 (18401)
2015 (24837)
2014 (22110)
2013 (18490)
2012 (20636)
2011 (20861)
2010 (20625)
Location
Africa (272)
Alabama (74)
Alaska (2)
Arizona (303)
Arkansas (11)
Asia (18404)
Australia (2201)
California (12261)
Canada (3146)
China (529)
Colorado (487)
Connecticut (415)
Delaware (210)
Europe (26050)
Florida (1780)
Georgia (381)
Hawaii (3)
Idaho (47)
Illinois (722)
India (51)
Indiana (335)
Iowa (16)
Japan (401)
Kansas (104)
Kentucky (31)
Louisiana (26)
Maine (26)
Maryland (1208)
Massachusetts (7950)
Michigan (312)
Minnesota (565)
Mississippi (5)
Missouri (82)
Montana (20)
Nebraska (13)
Nevada (115)
New Hampshire (61)
New Jersey (2661)
New Mexico (14)
New York (2844)
North Carolina (1293)
North Dakota (4)
Northern California (6050)
Ohio (287)
Oklahoma (15)
Oregon (20)
Pennsylvania (2284)
Puerto Rico (20)
Rhode Island (34)
South America (452)
South Carolina (78)
South Dakota (1)
Southern California (5146)
Tennessee (124)
Texas (1933)
United States (39283)
Utah (364)
Vermont (1)
Virginia (163)
Washington D.C. (45)
Washington State (938)
West Virginia (2)
Wisconsin (75)
495,396 Results for "anges inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients
March 4, 2026
·
3 min read
Press Releases
Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications
November 26, 2025
·
2 min read
Venture capital
Ollin parlays Vabysmo beat into $330M raise to test eye disease drug in Phase 3
With positive feedback on a Phase 3 trial design, Ollin Biosciences has collected a $330 million series B to advance its VEGF/Ang2 antibody, which bested Genentech’s therapy in a head-to-head study.
June 24, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
Innovent’s Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
September 18, 2025
·
5 min read
Angany announces First-in-Human Clinical Study on ANG-101, a Vaccine Candidate to Treat Cat Allergy
Angany Inc., announces that it has received clearance (Notice of Acceptance) from MHRA (Medicines and Healthcare Products Regulatory Agency) for the first clinical study to be conducted on its vaccine candidate ANG-101 to treat human allergy to cats.
October 5, 2023
·
3 min read
Press Releases
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
May 19, 2026
·
5 min read
Startups
Ollin Emerges From Stealth With $100M To Develop Eye Disease Bispecifics
OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster treatment for wet macular degeneration and diabetic macular edema.
September 17, 2025
·
2 min read
·
Tristan Manalac
Biotech Bay
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL).
January 18, 2024
·
6 min read
Drug Development
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study
Vasomune Therapeutics and AnGes drug candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study.
November 14, 2023
·
3 min read
Drug Development
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), in patients with homozygous familial hypercholesterolemia (HoFH).
May 23, 2023
·
7 min read
1 of 49,540
Next
